PE105399A1 - PROCEDIMIENTO PARA LA PREPARACION DE DERIVADOS DE 3a-(R)-BENCIL-2-METIL-2,3,3a,4,5,6,7-HEXAHIDRO-PIRAZOLO[4,3-c]PIRIDINA-3-ONA - Google Patents
PROCEDIMIENTO PARA LA PREPARACION DE DERIVADOS DE 3a-(R)-BENCIL-2-METIL-2,3,3a,4,5,6,7-HEXAHIDRO-PIRAZOLO[4,3-c]PIRIDINA-3-ONAInfo
- Publication number
- PE105399A1 PE105399A1 PE1998000546A PE00054698A PE105399A1 PE 105399 A1 PE105399 A1 PE 105399A1 PE 1998000546 A PE1998000546 A PE 1998000546A PE 00054698 A PE00054698 A PE 00054698A PE 105399 A1 PE105399 A1 PE 105399A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- bencil
- methyl
- procedure
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF] (Somatoliberin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
SE REFIERE A UN COMPUESTO I, DONDE n Y w SON 0-2; Y ES O o S; R1 ES H, -CN, -(CH2)qN(X6)C(O)X6, -(CH2)qN(X6)C(O)(CH2)t-A1, ENTRE OTROS; R2 ES H, ALQUILO C1-C8; ALQUILO(C CERO-C3)-(CICLOALQUILO C3-C8), ENTRE OTROS; R3 ES A1, ALQUILO C1-C10, ALQUILO (C1-C6)-A1, ENTRE OTROS; R4 ES H, ALQUILO C1-C6 o CICLOALQUILO C3-C7, o R3 Y R4 FORMAN UN CICLOALQUILO C5-C7, CICLOALQUENILO C5-C7, ENTRE OTROS; X4 ES H, ALQUILO C1-C6; o X4 Y R4 FORMAN UN ANILLO DE 5-7 MIEMBROS; R6 ES UN ENLACE o -Z1-(CH2)a-C(X5)(X5a)-(CH2)b-; a Y b SON 0-3; X5 Y X5a SON H, TRIFLUOROMETILO, A1, ENTRE OTROS; Z1 ES UN ENLACE, O o NX2; X2 ES H, ALQUILO C1-C6, ENTRE OTROS; R7 Y R8 SON H, ALQUILO C1-C6 OPCIONALMENTE SUSTITUIDO, ENTRE OTROS; A1 ES CICLOALQUENILO C5-C7, FENILO o ANILLO DE 4-8 MIEMBROS, ENTRE OTROS. UN COMPUESTO PREFERIDO ES 2-AMINO-N-[1-(3a-BENCIL-2-METIL-3-OXO-2,3,3a,4,6,7-HEXAHIDROPIRAZOLO[4,3-c)PIRIDIN-5-IL)-1-(1H-INDOL-3-ILMETIL)-2-OXO-ETIL]-ISOBUTIRAMIDA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO I ESTIMULA LA LIBERACION DE LA HORMONA DEL CRECIMIENTO POR LO QUE PUEDE SER UTIL PARA EL TRATAMIENTO DE LA RESISTENCIA A LA INSULINA, TRATAMIENTO O PREVENCION DE LA INSUFICIENCIA CARDIACA CONGESTIVA, OBESIDAD O DEBILIDAD ASOCIADA CON LA EDAD, TRASTORNOS DEL SUENO
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5079097P | 1997-06-25 | 1997-06-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE105399A1 true PE105399A1 (es) | 1999-11-04 |
Family
ID=21967444
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE1998000546A PE105399A1 (es) | 1997-06-25 | 1998-06-22 | PROCEDIMIENTO PARA LA PREPARACION DE DERIVADOS DE 3a-(R)-BENCIL-2-METIL-2,3,3a,4,5,6,7-HEXAHIDRO-PIRAZOLO[4,3-c]PIRIDINA-3-ONA |
Country Status (41)
Country | Link |
---|---|
US (3) | US6448263B1 (es) |
EP (1) | EP1000085B1 (es) |
JP (2) | JP2000514099A (es) |
KR (1) | KR20010014224A (es) |
CN (2) | CN1152049C (es) |
AP (1) | AP1145A (es) |
AR (1) | AR012256A1 (es) |
AT (1) | ATE305477T1 (es) |
AU (1) | AU747510B2 (es) |
BG (1) | BG104008A (es) |
BR (1) | BR9810477A (es) |
CA (1) | CA2294464A1 (es) |
CO (1) | CO4950621A1 (es) |
DE (1) | DE69831745T2 (es) |
DZ (1) | DZ2539A1 (es) |
EA (1) | EA002089B1 (es) |
EG (1) | EG21712A (es) |
ES (1) | ES2248899T3 (es) |
HK (1) | HK1028051A1 (es) |
HN (1) | HN1998000088A (es) |
HR (1) | HRP980361A2 (es) |
HU (1) | HUP0001922A3 (es) |
ID (1) | ID24345A (es) |
IL (7) | IL154116A0 (es) |
IN (1) | IN189724B (es) |
IS (1) | IS5275A (es) |
MA (1) | MA24581A1 (es) |
NO (1) | NO996205L (es) |
NZ (1) | NZ500655A (es) |
OA (1) | OA11242A (es) |
PA (1) | PA8452601A1 (es) |
PE (1) | PE105399A1 (es) |
PL (1) | PL337659A1 (es) |
SK (1) | SK175699A3 (es) |
TN (1) | TNSN98113A1 (es) |
TR (1) | TR199903257T2 (es) |
TW (1) | TW553943B (es) |
UA (1) | UA64751C2 (es) |
WO (1) | WO1998058949A1 (es) |
YU (1) | YU70199A (es) |
ZA (1) | ZA985546B (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA64751C2 (uk) | 1997-06-25 | 2004-03-15 | Пфайзер Продактс Інк. | Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти) |
UA53716C2 (uk) | 1997-06-25 | 2003-02-17 | Пфайзер Продактс Інк. | Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти) |
US6541634B2 (en) | 1999-02-26 | 2003-04-01 | Pfizer Inc. | Process for preparing growth hormone secretagogues |
US7721948B1 (en) * | 1999-05-25 | 2010-05-25 | Silverbrook Research Pty Ltd | Method and system for online payments |
EP1132388A3 (en) * | 2000-03-09 | 2004-03-03 | Pfizer Products Inc. | Hexahydropyrazolo[4,3-c]pyridine metabolites |
EP1159964B1 (en) | 2000-05-31 | 2009-10-28 | Pfizer Products Inc. | Use of growth hormone secretagogues for stimulating gastrointestinal motility |
IL145106A0 (en) * | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
CA2496687A1 (en) * | 2002-09-18 | 2004-04-01 | Centre Hospitalier De L'universite De Montreal (Chum) | Ghrh analogues |
US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
US7828934B2 (en) * | 2004-12-21 | 2010-11-09 | Hercules Incorporated | Reactive cationic resins for use as dry and wet strength agents in sulfite ion-containing papermaking systems |
US20070024388A1 (en) * | 2005-07-27 | 2007-02-01 | Hassan Tanbakuchi | Slabline structure with rotationally offset ground |
CU23558A1 (es) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento |
BRPI0807046A2 (pt) | 2007-02-09 | 2015-05-26 | Tranzyme Pharma Inc | Composto, composição farmacêutica, métodos de tratar um distúrbio, uma doença cardiovascular e um paciente que sofre de motilidade gastrointestinal reduzida ou disfuncional e, kit. |
US7862825B2 (en) * | 2007-02-21 | 2011-01-04 | Mladen Vranic | Method of controlling tight blood glucose by somatostatin receptor antagonists |
AR086554A1 (es) | 2011-05-27 | 2014-01-08 | Novartis Ag | Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina |
AU2013255458A1 (en) | 2012-05-03 | 2014-10-09 | Novartis Ag | L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists |
CN105164129B (zh) | 2013-05-28 | 2018-01-19 | 拉夸里亚创药株式会社 | 多晶型物形式 |
US9119832B2 (en) | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
JP6051392B1 (ja) * | 2014-08-05 | 2016-12-27 | ラクオリア創薬株式会社 | グレリン受容体アゴニストとしてのセリン誘導体 |
EP3212648A1 (en) * | 2014-10-31 | 2017-09-06 | RaQualia Pharma Inc. | Tetrahydropyrazolopyridine derivatives as ghrelin receptor agonists |
US20170121385A1 (en) | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3235550A (en) | 1966-02-15 | Anal g gesiaxoat t tail intravenous injection | ||
US3190802A (en) | 1961-10-09 | 1965-06-22 | Boehringer Sohn Ingelheim | Shaving composition and method of using same |
US4411890A (en) | 1981-04-14 | 1983-10-25 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
GB2101114B (en) | 1981-07-10 | 1985-05-22 | Farmos Group Ltd | Substituted imidazole derivatives and their preparation and use |
US5242783A (en) | 1991-07-31 | 1993-09-07 | Eastman Kodak Company | Photographic material and process |
CA2147503A1 (en) | 1992-11-06 | 1994-05-26 | Judith M. Pisano | Substituted dipeptide analogs promote release of growth hormone |
RU2168512C2 (ru) | 1992-12-11 | 2001-06-10 | Мерк Энд Ко., Инк. | Спиропиперидины, способы их получения (варианты) |
EP0739204A4 (en) | 1993-11-09 | 2000-03-15 | Merck & Co Inc | PIPERIDINE, PYRROLIDINE AND HEXAHYDRO-1H-AZEPINE SUPPORT THE RELEASE OF THE GROWTH HORMONE |
US5492916A (en) * | 1993-12-23 | 1996-02-20 | Merck & Co., Inc. | Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
BR9610277A (pt) | 1995-08-31 | 1999-07-06 | Schering Corp | Derivados de piperazino como antagonistas de neurowuinina |
EP0766966A3 (en) | 1995-09-08 | 2001-02-28 | Eli Lilly And Company | Method of treating insulin resistance |
PL327227A1 (en) | 1995-12-22 | 1998-12-07 | Novo Nordisk As | Compounds exhibiting growth hormone liberating properties |
TW432073B (en) | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
UA53716C2 (uk) | 1997-06-25 | 2003-02-17 | Пфайзер Продактс Інк. | Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти) |
AU7445498A (en) * | 1997-06-25 | 1999-01-04 | Pfizer Inc. | Dipeptide derivatives as growth hormone secretagogues |
UA64751C2 (uk) | 1997-06-25 | 2004-03-15 | Пфайзер Продактс Інк. | Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти) |
-
1998
- 1998-05-06 UA UA99127068A patent/UA64751C2/uk unknown
- 1998-06-04 HN HN1998000088A patent/HN1998000088A/es unknown
- 1998-06-05 IL IL15411698A patent/IL154116A0/xx unknown
- 1998-06-05 CN CNB988059231A patent/CN1152049C/zh not_active Expired - Fee Related
- 1998-06-05 IL IL13362698A patent/IL133626A0/xx unknown
- 1998-06-05 CA CA002294464A patent/CA2294464A1/en not_active Abandoned
- 1998-06-05 WO PCT/IB1998/000876 patent/WO1998058949A1/en not_active Application Discontinuation
- 1998-06-05 YU YU70199A patent/YU70199A/sh unknown
- 1998-06-05 ES ES98921683T patent/ES2248899T3/es not_active Expired - Lifetime
- 1998-06-05 IL IL15646598A patent/IL156465A/en not_active IP Right Cessation
- 1998-06-05 DE DE69831745T patent/DE69831745T2/de not_active Expired - Fee Related
- 1998-06-05 ID IDW991668A patent/ID24345A/id unknown
- 1998-06-05 IL IL15411198A patent/IL154111A0/xx unknown
- 1998-06-05 SK SK1756-99A patent/SK175699A3/sk unknown
- 1998-06-05 AT AT98921683T patent/ATE305477T1/de not_active IP Right Cessation
- 1998-06-05 TR TR1999/03257T patent/TR199903257T2/xx unknown
- 1998-06-05 PA PA19988452601A patent/PA8452601A1/es unknown
- 1998-06-05 JP JP11504029A patent/JP2000514099A/ja not_active Withdrawn
- 1998-06-05 EA EA199901075A patent/EA002089B1/ru not_active IP Right Cessation
- 1998-06-05 NZ NZ500655A patent/NZ500655A/en unknown
- 1998-06-05 AU AU74456/98A patent/AU747510B2/en not_active Ceased
- 1998-06-05 CN CNA2004100334189A patent/CN1530107A/zh active Pending
- 1998-06-05 IL IL15411598A patent/IL154115A0/xx unknown
- 1998-06-05 US US09/380,186 patent/US6448263B1/en not_active Expired - Fee Related
- 1998-06-05 PL PL98337659A patent/PL337659A1/xx unknown
- 1998-06-05 HU HU0001922A patent/HUP0001922A3/hu unknown
- 1998-06-05 EP EP98921683A patent/EP1000085B1/en not_active Expired - Lifetime
- 1998-06-05 IL IL15411498A patent/IL154114A0/xx unknown
- 1998-06-05 IL IL15411298A patent/IL154112A0/xx unknown
- 1998-06-05 BR BRPI9810477-2A patent/BR9810477A/pt not_active Application Discontinuation
- 1998-06-05 KR KR1019997012312A patent/KR20010014224A/ko active Search and Examination
- 1998-06-18 AP APAP/P/1998/001267A patent/AP1145A/en active
- 1998-06-22 TW TW087110014A patent/TW553943B/zh not_active IP Right Cessation
- 1998-06-22 PE PE1998000546A patent/PE105399A1/es not_active Application Discontinuation
- 1998-06-23 EG EG73598A patent/EG21712A/xx active
- 1998-06-23 AR ARP980103023A patent/AR012256A1/es not_active Application Discontinuation
- 1998-06-24 MA MA25139A patent/MA24581A1/fr unknown
- 1998-06-24 TN TNTNSN98113A patent/TNSN98113A1/fr unknown
- 1998-06-24 IN IN1755DE1998 patent/IN189724B/en unknown
- 1998-06-24 DZ DZ980149A patent/DZ2539A1/xx active
- 1998-06-25 ZA ZA9805546A patent/ZA985546B/xx unknown
- 1998-06-25 CO CO98036379A patent/CO4950621A1/es unknown
- 1998-06-25 HR HR60/050,790A patent/HRP980361A2/hr not_active Application Discontinuation
-
1999
- 1999-11-26 IS IS5275A patent/IS5275A/is unknown
- 1999-12-14 BG BG104008A patent/BG104008A/xx unknown
- 1999-12-15 NO NO996205A patent/NO996205L/no not_active Application Discontinuation
- 1999-12-21 OA OA9900300A patent/OA11242A/en unknown
-
2000
- 2000-11-23 HK HK00107485A patent/HK1028051A1/xx not_active IP Right Cessation
-
2002
- 2002-05-29 US US10/158,649 patent/US6630487B2/en not_active Expired - Fee Related
-
2003
- 2003-07-22 US US10/626,198 patent/US6867202B1/en not_active Expired - Fee Related
-
2004
- 2004-08-04 JP JP2004228301A patent/JP3742643B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE105399A1 (es) | PROCEDIMIENTO PARA LA PREPARACION DE DERIVADOS DE 3a-(R)-BENCIL-2-METIL-2,3,3a,4,5,6,7-HEXAHIDRO-PIRAZOLO[4,3-c]PIRIDINA-3-ONA | |
PE20010574A1 (es) | Derivados de indol como ligandos del receptor 5-ht2 | |
PE20060627A1 (es) | Derivados de pirazol condensado como agonistas de los receptores cannabinoides cb1 y/o cb2 | |
DE3887307D1 (de) | Sulfhydryl enthaltende tricylische Lactame und ihre pharmakologische Verwendung. | |
PE20010613A1 (es) | Antagonistas de la hormona concentradora de la melanina | |
PE20070336A1 (es) | Compuestos de indolina como agonistas de receptores adrenergicos alfa2c funcionalmente selectivos | |
KR880002834A (ko) | α-알킬-4-아미노-3-퀴놀린메탄올 및 1-(4-아르알킬아미노-3-퀴놀리닐) 알칸온, 이의 제조방법 및 약제로서의 용도 | |
CO4480108A1 (es) | Compuestos dipeptidos que son secretagogos de la hormona del crecimiento | |
AR057771A1 (es) | Agonistas adrenoreceptores alfa2c | |
PE20021067A1 (es) | Empleo de antagonistas del receptor nk3 | |
KR880012227A (ko) | 도파민 수용체 길항제의 신규사용법 | |
PE20001084A1 (es) | Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas | |
ES2084339T3 (es) | Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central. | |
KR900016196A (ko) | 테트라하이드로벤즈[c, d]인돌 세로토닌 효능제 | |
ES2032570T3 (es) | Derivados antiparkinson de ergolina. (reserva del art. 167.2 cpe). | |
ES2184083T3 (es) | Derivados de acilaminoalquenilen-amida como antagonistas de nk1 y nk2. | |
DK131084A (da) | Egolinderivater, fremgangsmaade til fremstilling heraf samt anvendelsen heraf som laegemiddel | |
AR006719A1 (es) | Derivados de bencilamina y formulacion farmaceutica que comprende a uno de dichos derivados. | |
NO173869C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,7-kondenserte 1h-indol-2-carboxylsre-n-(1,4-benzodiazepin-3-yl)-amider | |
KR950000146A (ko) | 테트라하이드로벤즈[cd]인돌-6-카복스아미드를 사용한 구토 예방 및 성기능부전의 치료방법 | |
ES2184989T3 (es) | Derivados de feniletanolaminotetralincarboxamida 3,4-disustituidos. | |
ATE183085T1 (de) | Behandlung und regulierung der augenentwicklung mit cholinergischen agonisten | |
ES2172029T3 (es) | 3-amino-1-cianofenil-uracilos. | |
UA41329C2 (uk) | Фармацевтична композиція для лікування порушень серцевого ритму у великих ссавців та людей, похідні 3-фенілсульфоніл-3,7-діазабіцикло[3,3,1]нонану та лікарський засіб для лікування аритмії | |
WO2003051291A3 (en) | Substituted 5-hydroxy-indole compounds for the treatment of glaucoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |